JP2022518496A - 微小血栓症を処置及び予防するためのプラスミノーゲン - Google Patents

微小血栓症を処置及び予防するためのプラスミノーゲン Download PDF

Info

Publication number
JP2022518496A
JP2022518496A JP2021542366A JP2021542366A JP2022518496A JP 2022518496 A JP2022518496 A JP 2022518496A JP 2021542366 A JP2021542366 A JP 2021542366A JP 2021542366 A JP2021542366 A JP 2021542366A JP 2022518496 A JP2022518496 A JP 2022518496A
Authority
JP
Japan
Prior art keywords
plasminogen
patient
plg
use according
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021542366A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518496A5 (https=
Inventor
シュテファン・テー・キーシク
リカルダ・ヴェルツ
ハンネ・リーケ・ゲルディンク
マルク・メイザー
ハンス－ヨアヒム・アンデルス
チョンスー・シー
クリストフ・シンメルプフェニッヒ
サティシュ・クマール・デヴァラプ
Original Assignee
プリビファーマ・コンサルティング・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プリビファーマ・コンサルティング・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical プリビファーマ・コンサルティング・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JP2022518496A publication Critical patent/JP2022518496A/ja
Publication of JP2022518496A5 publication Critical patent/JP2022518496A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021542366A 2019-01-24 2020-01-24 微小血栓症を処置及び予防するためのプラスミノーゲン Pending JP2022518496A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19153572.3 2019-01-24
EP19153572 2019-01-24
PCT/EP2020/051733 WO2020152322A1 (en) 2019-01-24 2020-01-24 Plasminogen for treating and preventing microthrombosis

Publications (2)

Publication Number Publication Date
JP2022518496A true JP2022518496A (ja) 2022-03-15
JP2022518496A5 JP2022518496A5 (https=) 2023-01-31

Family

ID=65234430

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021542366A Pending JP2022518496A (ja) 2019-01-24 2020-01-24 微小血栓症を処置及び予防するためのプラスミノーゲン

Country Status (9)

Country Link
US (1) US20220072110A1 (https=)
EP (1) EP3914288A1 (https=)
JP (1) JP2022518496A (https=)
KR (1) KR20210119428A (https=)
CN (1) CN113597313A (https=)
AU (1) AU2020212404B2 (https=)
BR (1) BR112021014068A2 (https=)
CA (1) CA3127375A1 (https=)
WO (1) WO2020152322A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022258590A1 (en) 2021-06-08 2022-12-15 Previpharma Consulting Gmbh Process for isolating plasminogen from a blood plasma fraction
WO2025132796A1 (en) 2023-12-21 2025-06-26 Previpharma Consulting Gmbh Process for isolating glu-plasminogen from a solution

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017077380A1 (en) * 2015-11-03 2017-05-11 Prometic Biotherapeutics, Inc. Plasminogen replacement therapy for plasminogen-deficiency
WO2018162754A1 (en) * 2017-03-09 2018-09-13 Previpharma Consulting Gmbh Preparing and use of glu-plasminogen from blood fractions
EP3395359A1 (en) * 2015-12-18 2018-10-31 Talengen International Limited Method for preventing or treating acute thrombosis and chronic thrombosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2254316B1 (https=) * 1973-12-18 1977-04-22 Choay Sa
US5520912A (en) 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
ES2982294T3 (es) * 2015-12-18 2024-10-15 Talengen Int Ltd Plasminógeno para su uso en el tratamiento o prevención de lesiones nerviosas por diabetes mellitus
DK3391902T5 (da) * 2015-12-18 2024-09-23 Talengen Int Ltd Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017077380A1 (en) * 2015-11-03 2017-05-11 Prometic Biotherapeutics, Inc. Plasminogen replacement therapy for plasminogen-deficiency
EP3395359A1 (en) * 2015-12-18 2018-10-31 Talengen International Limited Method for preventing or treating acute thrombosis and chronic thrombosis
WO2018162754A1 (en) * 2017-03-09 2018-09-13 Previpharma Consulting Gmbh Preparing and use of glu-plasminogen from blood fractions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
糖尿病, vol. 48, no. 10, JPN6024028712, 2005, pages 713 - 716, ISSN: 0005380063 *

Also Published As

Publication number Publication date
AU2020212404B2 (en) 2025-11-27
WO2020152322A1 (en) 2020-07-30
KR20210119428A (ko) 2021-10-05
EP3914288A1 (en) 2021-12-01
US20220072110A1 (en) 2022-03-10
CN113597313A (zh) 2021-11-02
AU2020212404A1 (en) 2021-08-26
BR112021014068A2 (pt) 2021-09-21
CA3127375A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
Jarrahi et al. Recombinant human DNase-I improves acute respiratory distress syndrome via neutrophil extracellular trap degradation
Hyers et al. Antithrombotic therapy for venous thromboembolic disease
Dickneite et al. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?
Been et al. Clinical effects and kinetic properties of intravenous APSAC—anisoylated plasminogen-streptokinase activator complex (BRL 26921) in acute myocardial infarction
McKenna Abnormal coagulation in the postoperative period contributing to excessive bleeding
JP7269184B2 (ja) 血液画分からのＧｌｕ－プラスミノーゲンの製造および使用
Wang et al. Embelin ameliorated sepsis-induced disseminated intravascular coagulation intensities by simultaneously suppressing inflammation and thrombosis
Schulman Studies on the medical treatment of deep vein thrombosis
JP2022518496A (ja) 微小血栓症を処置及び予防するためのプラスミノーゲン
JP2004075680A (ja) 止血補助因子としてｒｎａを含む医薬製剤
Bendapudi et al. How I diagnose and treat acute infection–associated purpura fulminans
Wu et al. Nattokinase-heparin exhibits beneficial efficacy and safety—An optimal strategy for CKD patients on hemodialysis
Penner Disseminated intravascular coagulation in patients with multiple organ failure of non-septic origin
LeVeen et al. Coagulopathy post peritoneovenous shunt
ES2628582T3 (es) Sulodexida para uso en el tratamiento de patologías en las que están involucradas metaloproteinasas
JP6826040B2 (ja) 安全かつ効果的な血栓溶解（Ｔｈｒｏｍｂｏｌｙｓｉｓ）のための方法および組成物
RU2813699C2 (ru) Плазминоген для лечения и профилактики микротромбоза
Novacek et al. Enhanced blood coagulation and enhanced fibrinolysis during hemodialysis with prostacyclin
Wang et al. Recombinant fibrinogenase from Agkistrodon acutus venom protects against sepsis via direct degradation of fibrin and TNF-α
Di Perri et al. Defibrotide therapy for thrombophlebitis–controlled clinical trial
JPH01180834A (ja) 血栓溶解剤
Bhagirath et al. Management of bleeding complications in the anticoagulated patient
Leithäuser et al. Antithrombin attenuates microvascular leakage and leukocyte-endothelial interaction in response to endotoxin
Chesterman et al. Thrombolytic therapy with streptokinase
Giles et al. The thrombogenicity of prothrombin complex concentrates: III. The relationship of in vivo thrombogenicity to the nature of the starting plasma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240424

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241129